Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
暂无分享,去创建一个
C. Pozzilli | G. Comi | M. Trojano | M. Inglese | A. Ghezzi | M. Zaffaroni | R. Bergamaschi | R. Totaro | S. Galgani | M. Salvetti | F. Patti | M. Amato | P. Sola | U. Aguglia | F. Granella | V. Brescia Morra | G. De Luca | P. Iaffaldano | E. Portaccio | M. Simone | E. Cocco | G. Lucisano | F. Logullo | G. Lus | E. Prestipino | L. Razzolini | L. Pastò | A. Bellinvia | M. Fonderico | C. Florio | E. Millefiorini | G. Salemi | R. Fratangelo | M. Vianello | G. Di Battista | M. Gatto | L. Tudisco | Mattia Fonderico | Angelo Bellinvia | Roberto Fratangelo
[1] Jeffrey A. Cohen,et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial , 2019, The Lancet Neurology.
[2] M. Sormani,et al. Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data , 2019, BMC Medicine.
[3] M. Ramanathan,et al. Epidemiology and treatment of multiple sclerosis in elderly populations , 2019, Nature Reviews Neurology.
[4] G. Fink,et al. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis , 2019, Current opinion in neurology.
[5] M. Sormani,et al. Clinical trials of disease-modifying agents in pediatric MS , 2019, Neurology.
[6] Xavier Montalban,et al. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis , 2019, Nature Reviews Neurology.
[7] Angelo Ghezzi,et al. The Italian multiple sclerosis register , 2018, Neurological Sciences.
[8] D. Centonze,et al. Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions , 2018, Front. Aging Neurosci..
[9] David K Howse,et al. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. , 2018, Multiple sclerosis and related disorders.
[10] T. Derfuss,et al. Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics , 2018, Expert review of neurotherapeutics.
[11] R. Alroughani,et al. Pediatric multiple sclerosis: a review , 2018, BMC Neurology.
[12] B. Vereijken,et al. Improved Prediction of Falls in Community-Dwelling Older Adults Through Phase-Dependent Entropy of Daily-Life Walking , 2018, Front. Aging Neurosci..
[13] M. Greenwood,et al. Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments , 2017, Front. Neurol..
[14] F. Ladeira,et al. The Influence of Menopause in Multiple Sclerosis Course: A Longitudinal Cohort Study , 2017, European Neurology.
[15] Marc Debouverie,et al. Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study , 2017, Neuroepidemiology.
[16] C. Pozzilli,et al. Prognostic indicators in pediatric clinically isolated syndrome , 2017, Annals of neurology.
[17] Xavier Montalban,et al. Treatment decisions in multiple sclerosis — insights from real-world observational studies , 2017, Nature Reviews Neurology.
[18] A. Traboulsee,et al. Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.
[19] C. Zhong,et al. Iron Deposition Leads to Neuronal α-Synuclein Pathology by Inducing Autophagy Dysfunction , 2017, Front. Neurol..
[20] A. Ghezzi,et al. Pediatric multiple sclerosis , 2016, Neurology.
[21] Alyssa H. Zhu,et al. Long‐term evolution of multiple sclerosis disability in the treatment era , 2016, Annals of neurology.
[22] Pierre Grammond,et al. Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis , 2016, Annals of neurology.
[23] H. Butzkueven,et al. Observational data: Understanding the real MS world , 2016, Multiple sclerosis.
[24] P. D. De Jager,et al. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort , 2016, Multiple sclerosis.
[25] P. Gustafson,et al. Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment , 2015, BioMed research international.
[26] J. Lechner-Scott,et al. Predictors of disability worsening in clinically isolated syndrome , 2015, Annals of clinical and translational neurology.
[27] C. Pozzilli,et al. Neuropsychological features in childhood and juvenile multiple sclerosis , 2014, Neurology.
[28] B. Weinshenker,et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis , 2013, Multiple sclerosis.
[29] M. Daumer,et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. , 2013, JAMA neurology.
[30] D. Arnold,et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.
[31] L. Kappos,et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis , 2012, Multiple sclerosis.
[32] L. Kappos,et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study , 2012, The Lancet Neurology.
[33] B. Healy,et al. Effect of gender on late-onset multiple sclerosis , 2012, Multiple sclerosis.
[34] A. Ghezzi,et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis , 2012, Multiple sclerosis.
[35] Christian Confavreux,et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. , 2011, The New England journal of medicine.
[36] P. Vermersch,et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis , 2011, The Lancet Neurology.
[37] L. Kappos,et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study , 2011, Therapeutic advances in neurological disorders.
[38] George C. Ebers,et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.
[39] Ludwig Kappos,et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[40] P. Vermersch,et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[41] Yinshan Zhao,et al. Impact of multiple sclerosis relapses on progression diminishes with time , 2009, Neurology.
[42] David H. Miller,et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.
[43] C. Pozzilli,et al. Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis , 2009, Annals of neurology.
[44] K. Selmaj,et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. , 2008, The New England journal of medicine.
[45] D. Arnold,et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.
[46] H. Tremlett,et al. Is late-onset multiple sclerosis associated with a worse outcome? , 2006, Neurology.
[47] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[48] S. Vukusic,et al. Age at disability milestones in multiple sclerosis. , 2006, Brain : a journal of neurology.
[49] S. Vukusic,et al. Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.
[50] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. , 2006, Brain : a journal of neurology.
[51] D. Paty,et al. Disability progression in multiple sclerosis is slower than previously reported , 2006, Neurology.
[52] A. Achiron,et al. Late‐Onset Multiple Sclerosis , 2001, Journal of the American Geriatrics Society.
[53] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[54] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[55] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[56] P. Vermersch,et al. Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. , 2012, Multiple sclerosis and related disorders.
[57] P. Vermersch,et al. Natural history of multiple sclerosis with childhood onset. , 2007, The New England journal of medicine.
[58] M. Finlayson. Concerns about the future among older adults with multiple sclerosis. , 2004, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.